OTC Drugs-Of-Abuse Assay Firms Should Provide Confirmatory Testing - Panel
This article was originally published in The Tan Sheet
Executive Summary
FDA should require manufacturers of OTC screening tests for drugs-of-abuse to cover the cost of confirmatory testing for presumptive positive results, members of FDA's Clinical Chemistry & Clinical Toxicology Devices panel recommended.
You may also be interested in...
FDA OTC Drugs Of Abuse Screening Kit Guide Clarifies Cost Bundling
FDA does not advise that OTC device manufacturers bundle the cost of primary and confirmation tests for home-use drugs of abuse test kits, the agency states in a draft guidance published in the Federal Register Dec. 2
FDA OTC Drugs Of Abuse Screening Kit Guide Clarifies Cost Bundling
FDA does not advise that OTC device manufacturers bundle the cost of primary and confirmation tests for home-use drugs of abuse test kits, the agency states in a draft guidance published in the Federal Register Dec. 2
FDA OTC Drugs Of Abuse Screening Kit Guide Clarifies Cost Bundling
FDA does not advise that OTC device manufacturers bundle the cost of primary and confirmation tests for home-use drugs of abuse test kits, the agency states in a draft guidance published in the Federal Register Dec. 2